Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Pitavastatin Tablets in 1mg, 2mg, and 4mg strengths.
The product is an AB-rated, generic equivalent to the brand product, LIVALO (pitavastatin) tablets.
Sawai USA, Inc, a company of Sawai Group Holdings Co., Ltd. (Sawai), has the ANDA for Pitavastatin tablets and it represents Sawai's first Paragraph IV product to be introduced in the United States. The company is distributing the product in the United States.
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia